stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Revenue
Aurinia Pharmaceuticals Inc's revenue for fiscal 2025 was $283.1M, up 20.4% from $235.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $321.7M. Over the past ten years it has ranged from $173.0K (fiscal 2016) to $283.1M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Aurinia Pharmaceuticals Inc ranks 53rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $283.1M | 20.38% |
| FY2024 | $235.1M | 33.97% |
| FY2023 | $175.5M | 30.95% |
| FY2022 | $134.0M | 193.89% |
| FY2021 | $45.6M | (9.00%) |
| FY2020 | $50.1M | 15,660.38% |
| FY2019 | $318.0K | (31.32%) |
| FY2018 | $463.0K | 10.77% |
| FY2017 | $418.0K | 141.62% |
| FY2016 | $173.0K | (26.38%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $83.7M | 0.58% |
| Jun 2026 | $83.2M | 7.10% |
| Mar 2026 | $77.7M | 0.77% |
| Dec 2025 | $77.1M | 4.96% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| ADMA ADMA Biologics Inc compare | $519.2M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc | $321.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $282.0M |
| PVLA Palvella Therapeutics, Inc. compare | $41.6M |
| IMNM Immunome, Inc. compare | $12.6M |
| CLDX Celldex Therapeutics, Inc. compare | $887.0K |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AUPH
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement